Ki-67 is a prognostic marker for hormone receptor positive tumors

Abstract

PurposeTo evaluate the utility of Ki67 as a prognostic marker in Luminal B node-negative breast cancer patients.MethodsWe identified 888 patients with invasive breast carcinomas who underwent surgery between 1997 and 2004. Several classical factors were collected: age, tumor size, node involvement, tumor grade, estrogen and progesterone receptors, HER2 and Ki-67 expression. We analyzed if these parameters could be considered as a prognostic factor. In early Luminal B group, we investigated which of the following biological features provide information about bad prognosis: lack of progesterone receptor expression, HER2 overexpression/amplification or high Ki-67 value.ResultsThe majority of patients were alive and without relapse of tumor at the moment of the analysis (70 %). The prognostic factors founded in multivariate analysis were: tumor size, node involvement, grade 3 and Ki-67 expression. When we stratified the sample by immunohistochemistry (IHC) in tumor subtypes, we assessed 680 patients and we observed 191 Luminal B tumors. The biological parameter related to the worst survival in absence of nodal involvement was Ki-67 value.ConclusionsKi-67 represents an additional predictor of survival in Luminal B node negative breast cancer. Conversely, neither Progesterone-receptor nor HER2 status proved prognostic significance in this group in our study.

Robust method for identification of prognostic gene signatures from gene expression profiles

“…If we conceive of mutations in terms of gain- or loss-of-function, we suggest that adverse gene mutations are gain-of-function mutations, also referred to as oncogenes, the expression levels of which have a negative relationship with prognosis. For example, a simple somatic mutation of MKI67 can be classified as a gain-of-function mutation based on our results, and the findings of a previous study showing that MKI67 is a proliferation marker 44 . Mutations in favorable genes may cause loss-of-function, and are thus considered tumor suppressor genes.…”

Ki-67 Prognostic Value in Different Histological Grades of Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma

“…The significance of Ki-67 protein as a prognostic marker has been widely studied, Ki-67 represents an additional predictor of survival in breast cancer (Pérez-López et al, 2016) cervical and uterine cancer, non-Hodgkin's lymphoma and large bowel cancer (Palmqvist et al, 1999), (Kimura et al, 2000), and the expression of Ki67 can be used as a prognostic biomarker in Colorectal cancer (CRC) (Melling et al, 2016). Furthermore, Ki-67 is considered to be one of the best predictors of survival (Wang et al, 2009) and recurrence (Wangsa et al, 2008).…”

Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor‐positive breast cancer

“…There is strong evidence for Ki67 as an additional prognostic marker, and it has also been shown to have predictive value . Ki67 may be particularly important in identifying Luminal B breast cancer . There are limitations of Ki67, particularly a lack of a standardized scoring system resulting in interlaboratory variation, different methods of measuring Ki67 and practical issues in implementing these for routine use in laboratories .…”